treat TB
Description of Research Outputs, 2009 - 2014
Research
BMJ 2014;349:g4643 doi: 10.1136/bmj.g4643 (Published 5 August 2014), 1-11
Q4: For people with dementia with associated depression, do antidepressants when compared to placebo/comparator produce benefits/harm in the specified outcomes?
Q2: In individuals with psychotic disorders (including schizophrenia), is the use of two or more antipsychotic medications concurrently more effective and safer than the use of one antipsychotic only?
Биполярное расстройство, известное так же, как маниакально-депрессивный психоз, является психическим заболеванием, которое характеризуется нетипичной сменой нас...троений, перепадами энергетического уровня и способности функционировать. Биполярное расстройство поддается лечению, и больные, страдающие этим заболеванием, способны жить полноценной и продуктивной жизнью.
more
F.No. INDO/FRC/442/2008-IHD | INDIAN COUNCIL OF MEDICAL RESEARCH
| New Delhi, the 1st July, 2014 | OFFICE MEMORANDUM
These Guidelines are intended to provide knowledge to the treating ophthalmologists, pediatricians, ocular oncologists, pediatric oncologists, and general physicians to arrive at an early diagnosis of retinoblastoma in the settings of district hospital, in private clinics and hospitals. The guidelin...es will enable the contact health personnel to refer at the right
time to the tertiary care hospital for management of retinoblastoma.
more
First Revised Edition
March 2000
Plos Current Outbreaks November 21, 2014
The Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patients.
PLoS Pathogens | www.plospathogens.org 1
February 2012 | Volume 8 | Issue 2 | e100246
CHAPTER 15:03 | Acts 14/1969, 62/1971, 35/1974, 20/1978, 41/1978 (s. 35) 39/1979, 7/1987, 11/1988, 18/1989 (s. 27), 1/1996, 6/2000, 22/2001; R.G.N. 899/1978.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.